Loading the security overview…
Where the tokens are
Standardised from the company’s filings, newest period first, labelled with the company’s own fiscal calendar. A line the company does not report is left off rather than shown as zero; margins and free cash flow are worked out here, and only where every input is present.
| Line item | Q2 FY262026-06-30 | Q1 FY262026-03-31 | Q4 FY252025-12-31 | Q3 FY252025-09-30 | Q2 FY252025-06-30 | Q1 FY252025-03-31 | Q4 FY242024-12-31 | Q3 FY242024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $256.15M | $164.90M | $202.13M | $207.64M | $194.43M | $157.21M | $181.89M | $182.55M |
| Cost of revenue | $4.06M | $2.88M | $2.55M | $4.60M | $3.43M | $2.40M | $2.96M | $2.87M |
| Gross profit | $252.09M | $162.02M | $199.58M | $203.04M | $191.00M | $154.81M | $178.93M | $179.68M |
| Gross margin | 98.4% | 98.3% | 98.7% | 97.8% | 98.2% | 98.5% | 98.4% | 98.4% |
| Research and development | $53.89M | $66.27M | $64.86M | $68.85M | $60.47M | $60.74M | $70.30M | $59.34M |
| Selling, general and administrative | $156.90M | $145.36M | $130.24M | $123.98M | $103.85M | $90.66M | $83.37M | $73.75M |
| Operating expenses | $210.79M | $211.62M | $195.09M | $192.82M | $164.32M | $151.40M | $153.67M | $133.08M |
| Operating income | $41.30M | −$49.60M | $4.49M | $10.22M | $26.68M | $3.42M | $25.26M | $46.60M |
| Operating margin | 16.1% | -30.1% | 2.2% | 4.9% | 13.7% | 2.2% | 13.9% | 25.5% |
| EBITDA | $42.16M | −$49.00M | $4.78M | $10.51M | $27.14M | $3.88M | $25.54M | $46.92M |
| Interest income | $4.63M | $4.89M | $0 | — | $5.02M | $6.20M | $0 | — |
| Income before taxes | $45.93M | −$44.72M | $9.91M | $15.24M | $31.69M | $9.62M | $31.96M | $52.94M |
| Income taxes | $2.94M | −$12.95M | −$14.38M | −$4.43M | −$3.46M | −$10.93M | $1.21M | $5.73M |
| Net income | $42.99M | −$31.76M | $24.29M | $19.67M | $35.15M | $20.55M | $30.75M | $47.21M |
| Net margin | 16.8% | -19.3% | 12.0% | 9.5% | 18.1% | 13.1% | 16.9% | 25.9% |
| EPS, basic | $0.40 | −$0.30 | $0.23 | $0.19 | $0.33 | $0.19 | $0.29 | $0.45 |
| EPS, diluted | $0.36 | −$0.30 | $0.20 | $0.16 | $0.29 | $0.17 | $0.26 | $0.41 |
| Diluted shares | 118.39M | 104.44M | 120.21M | 119.44M | 120.49M | 119.82M | 119.04M | 113.72M |
Figures describe Corcept Therapeutics shares, not any token. As of Jul 29, 2026, from Massive's standardised financials. The company reports these figures; a token's issuer holds the shares and reports nothing of its own here.